Search
Iterum Therapeutics PLC
ITRMAdd to Watchlist
0.030USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
2.66MMarket Cap
LossP/E TTM
More Details of Iterum Therapeutics PLC Company
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Iterum Therapeutics PLC Info
Ticker SymbolITRM
Company nameIterum Therapeutics PLC
IPO dateMay 25, 2018
CEOFishman (Corey N)
Number of employees9
Security typeOrdinary Share
Fiscal year-endMay 25
Address3 Dublin Landings
CityDUBLIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIreland
Postal codeD01 C4E0
Phone35319038354
Websitehttps://www.iterumtx.com/
Ticker SymbolITRM
IPO dateMay 25, 2018
CEOFishman (Corey N)
Company Executives of Iterum Therapeutics PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Michael W. Dunne, M.D.
Dr. Michael W. Dunne, M.D.
Director
Director
241.00K
+2.49%
Mr. Corey N. Fishman
Mr. Corey N. Fishman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
137.06K
--
Ms. Beth P. Hecht, J.D.
Ms. Beth P. Hecht, J.D.
Independent Director
Independent Director
18.84K
--
Ms. Judith M. Matthews
Ms. Judith M. Matthews
Chief Financial Officer
Chief Financial Officer
8.13K
--
Mr. David G. Kelly
Mr. David G. Kelly
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Joseph John (Joe) Whalen
Mr. Joseph John (Joe) Whalen
Independent Director
Independent Director
--
--
Ms. Christine Coyne
Ms. Christine Coyne
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Michael W. Dunne, M.D.
Dr. Michael W. Dunne, M.D.
Director
Director
241.00K
+2.49%
Mr. Corey N. Fishman
Mr. Corey N. Fishman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
137.06K
--
Ms. Beth P. Hecht, J.D.
Ms. Beth P. Hecht, J.D.
Independent Director
Independent Director
18.84K
--
Ms. Judith M. Matthews
Ms. Judith M. Matthews
Chief Financial Officer
Chief Financial Officer
8.13K
--
Mr. David G. Kelly
Mr. David G. Kelly
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Joseph John (Joe) Whalen
Mr. Joseph John (Joe) Whalen
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Iterum Therapeutics PLC?
The top five shareholders of Iterum Therapeutics PLC are: Dr. Michael W. Dunne, M.D.
How many institutions hold shares of Iterum Therapeutics PLC (ITRM)?
As of 2026Q1, 55 institutions hold shares of Iterum Therapeutics PLC, with a combined market value of approximately 944.04K, accounting for 1.77% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -3957996.00.